Fla. jury awards $250K in Zometa jaw injury suit 
Published: March 18, 2013
Tags: failure to warn, loss of consortium, Novartis Pharmaceuticals, osteonecrosis, product liability, Zometa
A federal jury has awarded $250,000 to a Florida couple who claimed Novartis Pharmaceuticals failed to adequately warn of the risk of osteonecrosis of the jaw from taking the bone strengthening drug Zometa.
J. Hunter Chiles III will received $200,000 in compensatory damages under a » Continue Reading.
Fosamax suit can’t proceed based on ‘sham’ issue
Published: February 4, 2013
Tags: expert testimony, failure to warn, Fosamax, Merck, osteonecrosis, product liability
Irreconcilable contradictions in expert testimony prevented a product liability plaintiff from establishing that Merck failed to provide adequate warnings with the osteoporosis drug Fosamax, the 2nd Circuit has ruled in affirming judgment.
Fosamax litigation ready for next step in bellwether cases
By:
Correy Stephenson
Published: December 4, 2012
Tags: drug litigation, femur fracture, Fosamax, Merck, multidistrict litigation, osteonecrosis
Six years after the first Fosamax lawsuit was filed, litigation over the osteoporosis drug is about to start a new chapter.
The suits against Merck, the drug’s manufacturer, fall into two categories: plaintiffs alleging they suffer from osteonecrosis, or jaw damage, and those claiming they suffered a non-traumatic femur fracture as a result of taking the drug.
Benchmarks: N.J. court upholds Novartis win in Zometa bellwether trial
Published: June 14, 2012
Tags: Aredia, Novartis, ONJ, osteonecrosis, osteonecrosis of the jaw, product liability, Zometa
A New Jersey appeals court yesterday upheld a defense verdict for Novartis Pharmaceuticals in a product liability lawsuit brought by a woman who claimed she developed osteonecrosis of the jaw after taking Aredia and Zometa.
Special master appointed to help settle Fosamax cases
Published: December 7, 2011
Tags: Fosamax, Merck, osteonecrosis, osteoporosis
After mixed results in bellwether cases, and a recent string of defense verdicts, a special settlement master has been appointed to the Fosamax multidistrict litigation.
New warning label excluded from Zometa trial
Published: April 18, 2011
Tags: Novartis, ONJ, osteonecrosis, product liability, Zometa
A product liability plaintiff could not introduce evidence that the defendant added a new warning label to the osteoporosis drug that allegedly injured her husband, a U.S. District Court in New York has ruled in granting a motion in limine.
First state trial in Fosamax case ends with defense win
By:
Sylvia Hsieh
Published: February 25, 2011
Tags: drug litigation, Fosamax, multidistrict litigation, osteonecrosis, osteoporosis
In the first bellwether state trial over the osteoporosis drug Fosamax, Merck won a defense verdict last week.
Class action tolling preserves Zometa claim
By:
Pat Murphy
Published: January 14, 2011
Tags: class action, osteonecrosis, products liability, statute of limitations, Zometa
The doctrine of class action tolling applied to preserve the product liability lawsuit of a woman who claimed she suffered osteonecrosis of the jaw as a result of taking the prescription drug Zometa, the Montana Supreme Court has ruled.
Drug company hit with $13 million failure-to-warn verdict
By:
Sylvia Adcock
Published: December 3, 2010
Tags: Aredia, failure to warn, Novartis, osteonecrosis, product liability, Zometa
A federal jury in North Carolina has returned a verdict of nearly $13 million against pharmaceutical giant Novartis, saying the company failed to adequately warn patients and doctors about the risks of taking the bone-strengthening drugs Zometa and Aredia.
Next Fosamax trial nears
By:
Nora Tooher
Published: September 21, 2010
Tags: Fosamax, Merck, osteonecrosis, product liability
Jury selection in the third Fosamax bellwether trial is slated for Oct. 28 in U.S. District Court for the Southern District of New York.
